Q-Griffithsin

DRUG2 trials

Sponsors

Kenneth Palmer, Sharon Hillier

Conditions

COVID-19COVID-19 PreventionPharmacokineticsSafety

Phase 1

PREVENT-COVID-19: A Q-Griffithsin Intranasal Spray

CompletedNCT05122260

Kenneth PalmerCOVID-19 Prevention

Start: 2021-11-11End: 2022-02-14Updated: 2022-04-29

Safety and Acceptability of Q GRFT Nasal Spray for COVID-19 Prophylaxis

CompletedNCT05180500

Sharon HillierCOVID-19, Pharmacokinetics, Safety

Start: 2022-03-15End: 2022-12-07Updated: 2024-04-23

Related Papers

Development and validation of a product acceptability questionnaire for intranasal Q-Griffithsin COVID-19 prophylaxis (SPRAY PAL)

BMJ Open2023-09-011 citations